A single centre registry study to evaluate the safety and efficacy rivaroxaban in patients with venous thromboembolism and active malignancy.
Latest Information Update: 10 Feb 2016
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 10 Feb 2016 New trial record
- 18 Jan 2016 Results published in the American Journal of Medicine